A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis

Leon A. Adams, Paul Angulo, Jan Petz, Jill Keach, Keith Lindor

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: Standard dose (13-15 mg/kg) ursodeoxycholic acid (UCDA) is ineffective in the treatment of nonalcoholic steatohepatitis (NASH), however, its immunomodulatory and hepatoprotective effects are dose related. Therefore, we examined the impact of high-dose (28-32 mg/kg) UCDA on aminotransaminase levels in a pilot study of patients with NASH. Methods: Twelve patients with biopsy-proven NASH and elevated aminotransaminases were prescribed high-dose UCDA for 6 months. Liver function tests were monitored during and after treatment with the study endpoint defined as normalization of aminotransaminase levels. Results: Normalization of aspartate aminotransaminase (AST) levels was observed in two (17%) patients, however, no patient normalized their alanine aminotransaminase (ALT) levels. A trend towards a minor reduction in median (range) ALT values from baseline to end of treatment was noted [124 (66-229) vs. 101 (53-188) IU/l, p = 0.07], whereas AST levels remained unchanged [85 (40-132) vs. 98 (28-147) IU/l, p = 0.83]. One patient discontinued treatment prematurely due to diarrhea. No significant change in fasting glucose, triglyceride or HDL cholesterol was observed with treatment. No significant change in ALT or AST levels was observed in the 6-month period after cessation of treatment. Conclusion: High-dose UCDA does not normalize aminotransaminase levels in patients with NASH. Other inexpensive well-tolerated agents for the treatment of NASH need to be investigated.

Original languageEnglish (US)
Pages (from-to)628-633
Number of pages6
JournalHepatology International
Volume4
Issue number3
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Aspartic Acid
Alanine
Therapeutics
Withholding Treatment
Liver Function Tests
HDL Cholesterol
Non-alcoholic Fatty Liver Disease
Diarrhea
Fasting
Triglycerides
Biopsy
Glucose

Keywords

  • Aminotransaminase
  • Nonalcoholic steatohepatitis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology

Cite this

A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. / Adams, Leon A.; Angulo, Paul; Petz, Jan; Keach, Jill; Lindor, Keith.

In: Hepatology International, Vol. 4, No. 3, 09.2010, p. 628-633.

Research output: Contribution to journalArticle

Adams, Leon A. ; Angulo, Paul ; Petz, Jan ; Keach, Jill ; Lindor, Keith. / A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. In: Hepatology International. 2010 ; Vol. 4, No. 3. pp. 628-633.
@article{9f29a9888881490da489885a46f1fa3d,
title = "A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis",
abstract = "Purpose: Standard dose (13-15 mg/kg) ursodeoxycholic acid (UCDA) is ineffective in the treatment of nonalcoholic steatohepatitis (NASH), however, its immunomodulatory and hepatoprotective effects are dose related. Therefore, we examined the impact of high-dose (28-32 mg/kg) UCDA on aminotransaminase levels in a pilot study of patients with NASH. Methods: Twelve patients with biopsy-proven NASH and elevated aminotransaminases were prescribed high-dose UCDA for 6 months. Liver function tests were monitored during and after treatment with the study endpoint defined as normalization of aminotransaminase levels. Results: Normalization of aspartate aminotransaminase (AST) levels was observed in two (17{\%}) patients, however, no patient normalized their alanine aminotransaminase (ALT) levels. A trend towards a minor reduction in median (range) ALT values from baseline to end of treatment was noted [124 (66-229) vs. 101 (53-188) IU/l, p = 0.07], whereas AST levels remained unchanged [85 (40-132) vs. 98 (28-147) IU/l, p = 0.83]. One patient discontinued treatment prematurely due to diarrhea. No significant change in fasting glucose, triglyceride or HDL cholesterol was observed with treatment. No significant change in ALT or AST levels was observed in the 6-month period after cessation of treatment. Conclusion: High-dose UCDA does not normalize aminotransaminase levels in patients with NASH. Other inexpensive well-tolerated agents for the treatment of NASH need to be investigated.",
keywords = "Aminotransaminase, Nonalcoholic steatohepatitis, Ursodeoxycholic acid",
author = "Adams, {Leon A.} and Paul Angulo and Jan Petz and Jill Keach and Keith Lindor",
year = "2010",
month = "9",
doi = "10.1007/s12072-010-9195-1",
language = "English (US)",
volume = "4",
pages = "628--633",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis

AU - Adams, Leon A.

AU - Angulo, Paul

AU - Petz, Jan

AU - Keach, Jill

AU - Lindor, Keith

PY - 2010/9

Y1 - 2010/9

N2 - Purpose: Standard dose (13-15 mg/kg) ursodeoxycholic acid (UCDA) is ineffective in the treatment of nonalcoholic steatohepatitis (NASH), however, its immunomodulatory and hepatoprotective effects are dose related. Therefore, we examined the impact of high-dose (28-32 mg/kg) UCDA on aminotransaminase levels in a pilot study of patients with NASH. Methods: Twelve patients with biopsy-proven NASH and elevated aminotransaminases were prescribed high-dose UCDA for 6 months. Liver function tests were monitored during and after treatment with the study endpoint defined as normalization of aminotransaminase levels. Results: Normalization of aspartate aminotransaminase (AST) levels was observed in two (17%) patients, however, no patient normalized their alanine aminotransaminase (ALT) levels. A trend towards a minor reduction in median (range) ALT values from baseline to end of treatment was noted [124 (66-229) vs. 101 (53-188) IU/l, p = 0.07], whereas AST levels remained unchanged [85 (40-132) vs. 98 (28-147) IU/l, p = 0.83]. One patient discontinued treatment prematurely due to diarrhea. No significant change in fasting glucose, triglyceride or HDL cholesterol was observed with treatment. No significant change in ALT or AST levels was observed in the 6-month period after cessation of treatment. Conclusion: High-dose UCDA does not normalize aminotransaminase levels in patients with NASH. Other inexpensive well-tolerated agents for the treatment of NASH need to be investigated.

AB - Purpose: Standard dose (13-15 mg/kg) ursodeoxycholic acid (UCDA) is ineffective in the treatment of nonalcoholic steatohepatitis (NASH), however, its immunomodulatory and hepatoprotective effects are dose related. Therefore, we examined the impact of high-dose (28-32 mg/kg) UCDA on aminotransaminase levels in a pilot study of patients with NASH. Methods: Twelve patients with biopsy-proven NASH and elevated aminotransaminases were prescribed high-dose UCDA for 6 months. Liver function tests were monitored during and after treatment with the study endpoint defined as normalization of aminotransaminase levels. Results: Normalization of aspartate aminotransaminase (AST) levels was observed in two (17%) patients, however, no patient normalized their alanine aminotransaminase (ALT) levels. A trend towards a minor reduction in median (range) ALT values from baseline to end of treatment was noted [124 (66-229) vs. 101 (53-188) IU/l, p = 0.07], whereas AST levels remained unchanged [85 (40-132) vs. 98 (28-147) IU/l, p = 0.83]. One patient discontinued treatment prematurely due to diarrhea. No significant change in fasting glucose, triglyceride or HDL cholesterol was observed with treatment. No significant change in ALT or AST levels was observed in the 6-month period after cessation of treatment. Conclusion: High-dose UCDA does not normalize aminotransaminase levels in patients with NASH. Other inexpensive well-tolerated agents for the treatment of NASH need to be investigated.

KW - Aminotransaminase

KW - Nonalcoholic steatohepatitis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=77958100236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958100236&partnerID=8YFLogxK

U2 - 10.1007/s12072-010-9195-1

DO - 10.1007/s12072-010-9195-1

M3 - Article

C2 - 21063487

AN - SCOPUS:77958100236

VL - 4

SP - 628

EP - 633

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 3

ER -